- Q1 2024 Relmada Therapeutics Inc Earnings Call TranscriptMay 08, 2024€3.54Earnings
- Q4 2023 Relmada Therapeutics Inc Earnings Call TranscriptMar 19, 2024€4.98 (-1.39%)Earnings
- Q3 2023 Relmada Therapeutics Inc Earnings Call TranscriptNov 08, 2023€2.78 (-4.79%)Earnings
- Q2 2023 Relmada Therapeutics Inc Earnings Call TranscriptAug 08, 2023€2.36 (+4.42%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Relmada Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Relmada Therapeutics Inc Earnings Call TranscriptMay 11, 2023€2.94 (-2.65%)Earnings
- Q4 2022 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2023€2.16 (-5.26%)Earnings
- Relmada Therapeutics Inc Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder - Corporate Call TranscriptDec 07, 2022
- Q3 2022 Relmada Therapeutics Inc Earnings Call TranscriptNov 10, 2022€5.9Earnings
- Q2 2022 Relmada Therapeutics Inc Earnings Call TranscriptAug 11, 2022€28 (+6.06%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Q1 2022 Relmada Therapeutics Inc Earnings Call TranscriptMay 05, 2022€22.6 (-3.42%)Earnings
- Q4 2021 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2022€21.2 (+8.72%)Earnings
- Relmada Therapeutics Inc Results of Human Abuse Potential Study of REL-1017 vs. Ketamine - Corporate Call TranscriptFeb 23, 2022
- Q3 2021 Relmada Therapeutics Inc Earnings Call TranscriptNov 11, 2021€21.4Earnings
- Relmada Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Relmada Therapeutics Inc Earnings Call TranscriptAug 10, 2021€19 (-3.55%)Earnings
- Relmada Therapeutics Inc REL-1017 Clinical Data Update Call TranscriptJul 27, 2021
- Q1 2021 Relmada Therapeutics Inc Earnings Call TranscriptMay 12, 2021€28.2Earnings
- Q4 2020 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2021€29 (+0.17%)Earnings
Q4 2023 Relmada Therapeutics Inc Earnings Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the Relmada Therapeutics, Inc. Fourth Quarter and Full Year 2022 Results Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call, a recording needed assistance, please press star zero for the operator, and this call is being recorded on Tuesday, March 19th, 2024.
I would now like to turn the conference over to Tim McCarthy. Thank you. Please go ahead.
Thank you, operator, and thank you all for joining us this afternoon. With me on today's call are Chief Executive Officer, Sergio Traversa; and Chief Financial Officer, Maged Shenouda. This afternoon Relmada issued a press release providing a business update announcing financial results for the three and 12 months ended December 31st, 2023.
Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)